Sotyktu

RSS

deucravacitinib

Authorised
This medicine is authorised for use in the European Union.

Overview

Sotyktu is a medicine for treating adults with moderate to severe plaque psoriasis (an inflammatory disease causing red, scaly patches on the skin) who are eligible for systemic therapy (treatment with a medicine given by mouth or by injection).

Sotyktu contains the active substance deucravacitinib.

This EPAR was last updated on 31/03/2023

Authorisation details

Product details
Name
Sotyktu
Agency product number
EMEA/H/C/005755
Active substance
Deucravacitinib
International non-proprietary name (INN) or common name
deucravacitinib
Therapeutic area (MeSH)
Psoriasis
Anatomical therapeutic chemical (ATC) code
L04AA
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Bristol-Myers Squibb Pharma EEIG
Date of issue of marketing authorisation valid throughout the European Union
24/03/2023
Contact address

Plaza 254
Blanchardstown Corporate Park 2
Dublin 15
D15 T867
Ireland

Product information

24/03/2023 Sotyktu - EMEA/H/C/005755 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Immunosuppressants

Therapeutic indication

Treatment of moderate-to-severe plaque psoriasis in adults.

Assessment history

How useful was this page?

Add your rating
Average
2 ratings